The estimated Net Worth of Bruce D Given is at least $30.8 Million dollars as of 27 April 2020. Dr Given owns over 5,401 units of Arrowhead Pharmaceuticals stock worth over $17,814,286 and over the last 13 years he sold ARWR stock worth over $12,498,927. In addition, he makes $486,308 as Advisor at Arrowhead Pharmaceuticals.
Dr has made over 14 trades of the Arrowhead Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 5,401 units of ARWR stock worth $216,040 on 27 April 2020.
The largest trade he's ever made was selling 242,834 units of Arrowhead Pharmaceuticals stock on 8 February 2019 worth over $3,895,057. On average, Dr trades about 30,165 units every 33 days since 2012. As of 27 April 2020 he still owns at least 850,730 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Dr Given stock trades at the bottom of the page.
Dr. Bruce D. Given is the Advisor at Arrowhead Pharmaceuticals.
As the Advisor of Arrowhead Pharmaceuticals, the total compensation of Dr Given at Arrowhead Pharmaceuticals is $486,308. There are 10 executives at Arrowhead Pharmaceuticals getting paid more, with Christopher Anzalone having the highest compensation of $2,216,260.
Dr Given is 66, he's been the Advisor of Arrowhead Pharmaceuticals since . There are 2 older and 15 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.
Bruce's mailing address filed with the SEC is 177 E. COLORADO BLVD, SUITE 700, PASADENA, CA, 91105.
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone, and Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: